Utility of urinary biomarkers in predicting loss of residual renal function: the balANZ trial

Cho, Yeoungjee, Johnson, David W., Vesey, David A., Hawley, Carmel M., Clarke, Margaret and Topley, Nicholas (2015) Utility of urinary biomarkers in predicting loss of residual renal function: the balANZ trial. Peritoneal Dialysis International, 35 2: 159-171. doi:10.3747/pdi.2013.00170


Author Cho, Yeoungjee
Johnson, David W.
Vesey, David A.
Hawley, Carmel M.
Clarke, Margaret
Topley, Nicholas
Title Utility of urinary biomarkers in predicting loss of residual renal function: the balANZ trial
Formatted title
Utility of urinary biomarkers in predicting loss of residual renal function: the balANZ trial
Journal name Peritoneal Dialysis International   Check publisher's open access policy
ISSN 0896-8608
1718-4304
Publication date 2015-03
Sub-type Article (original research)
DOI 10.3747/pdi.2013.00170
Open Access Status DOI
Volume 35
Issue 2
Start page 159
End page 171
Total pages 13
Place of publication Milton, ON, Canada
Publisher Multimed
Collection year 2016
Language eng
Formatted abstract
Background: The ability of urinary biomarkers to predict residual renal function (RRF) decline in peritoneal dialysis (PD) patients has not been defined. The present study aimed to explore the utility of established biomarkers from kidney injury models for predicting loss of RRF in incident PD patients, and to evaluate the impact on RRF of using neutral-pH PD solution low in glucose degradation products.

Methods: The study included 50 randomly selected participants from the balANZ trial who had completed 24 months of follow-up. A change in glomerular filtration rate (GFR) was used as the primary clinical outcome measure. In a mixed-effects general linear model, baseline measurements of 18 novel urinary biomarkers and albumin were used to predict GFR change. The model was further used to evaluate the impact of biocompatible PD solution on RRF, adjusted for each biomarker.

Results: Baseline albuminuria was not a useful predictor of change in RRF in PD patients (p = 0.84). Only clusterin was a significant predictor of GFR decline in the whole population (p = 0.04, adjusted for baseline GFR and albuminuria). However, the relationship was no longer apparent when albuminuria was removed from the model (p = 0.31). When the effect of the administered PD solutions was examined using a model adjusted for PD solution type, baseline albuminuria, and GFR, higher baseline urinary concentrations of trefoil factor 3 (TFF3, p = 0.02), kidney injury molecule 1 (KIM-1, p = 0.04), and interferon γ-induced protein 10 (IP-10, p = 0.03) were associated with more rapid decline of RRF in patients receiving conventional PD solution compared with biocompatible PD solution.

Conclusions: Higher urinary levels of kidney injury biomarkers (TFF3, KIM-1, IP-10) at baseline predicted significantly slower RRF decline in patients receiving biocompatible PD solutions. Findings from the present investigation should help to guide future studies to validate the utility of urinary biomarkers as tools to predict RRF decline in PD patients.
Keyword Biocompatibility
Biomarkers
Glucose degradation products
Kidney injury
Residual renal function
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 17 May 2015, 01:45:30 EST by System User on behalf of Scholarly Communication and Digitisation Service